Navigation Links
FDA Warns of Painkiller Mix-Up at Nebraska Plant
Date:1/9/2012

By Steven Reinberg
HealthDay Reporter

MONDAY, Jan. 9 (HealthDay News) -- The U.S. Food and Drug Administration issued a warning on Monday that some narcotic prescription painkillers made at a Nebraska plant may have been mixed up with some over-the-counter medicines packaged at the same facility.

"We issued a public health advisory to health care professionals and patients about a potential problem with opioid products manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health at its Lincoln, Nebraska, site," Dr. Edward Cox, director of the FDA's Office of Antiviral Products in the Office of New Drugs at the Center for Drug Evaluation and Research, said during a morning news conference.

On Sunday, Novartis issued a recall for some over-the-counter medications made at the same plant. These included Excedrin, NoDoz, Bufferin and Gas-X, Cox said.

"Mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended, or receiving an unintended ingredient," Novartis said in the Sunday news release. "This could potentially result in overdose, interaction with other medications a consumer may be taking, or an allergic reaction if the consumer is allergic to the unintended ingredient."

Cox noted that it is possible, but unlikely, that these over-the-counter medications and prescription opioid painkillers could be mixed up together, although "we are still looking into this."

The narcotic painkillers in question include Opana, Percocet, Endocet and Zydone.

The problem occurred because the machinery used to package these products can retain pills from a previous packaging run, Cox explained.

"This could result in an incorrect pill ending up in the bottle of another product," Cox explained. "The likelihood of this occurring in medication dispensed to patients is estimated to be low."

Endo Pharmaceuticals officials claim they know of only three such mix-ups since 2009, Cox said. Moreover, the company is not aware of any patients who took the wrong pills or of "any adverse effects attributable to a product mix-up," Cox added.

The company and the FDA are providing information to help patients identify any stray pills. "We are asking patients to check their medicines to identify any pills of a different size, shape or color from their regular medicine," Cox said.

If any pills differ from the rest in the bottle, patients should stop taking their medicine and take the bottle to their pharmacist, Cox said.

Until these problems are fixed, manufacturing at the plant will remain shut down, the company said. Customers can call 1-888-477-2403 Monday to Friday, from 9 a.m. to 8 p.m., while patients can call Endo Pharmaceuticals' call center at 1-800-462-3636.

During the closure, there may be a shortage of certain painkillers, but several alternatives are available, the FDA noted.

Cox said that the agency decided not to issue a recall because of the small chance of a patient taking the wrong pill and the need for these prescription painkillers.

"After carefully considering the public health risks, [the] FDA does not believe that a recall of Endo's opioid analgesic product is warranted," Cox said.

Cox added that this plant has had problems in the past, and that the FDA's investigation is ongoing.

More information

For more on the painkiller mix-up, visit the U.S. Food and Drug Administration.

SOURCES: Jan. 9, 2012, press conference with: Edward Cox, M.D., director, Office of Antiviral Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Jan. 8, 2012, press release, Novartis Consumer Health


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Diet Still Has Too Much Salt, CDC Warns
2. Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns
3. The Hype on Hypoallergenic Dogs Is Just That, Study Warns
4. CDC Warns Against Exposure to Mad Cow-Like Brain Diseases
5. Long-Term Ecstasy Users at Risk for Brain Damage, Study Warns
6. Research Warns of Overuse of Powerful Class of Antibiotics
7. Snow Shoveling Injuries Affect Old and Young, Expert Warns
8. Dont Let the Bedbugs Bite, Allergist Warns
9. Study Warns of Risks for Early Dialysis
10. Bone Drugs Linked to Rare Fractures, FDA Warns
11. Don't Drink and Drive on Fourth of July Weekend, Washington, D.C., Attorney Warns
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Warns of Painkiller Mix-Up at Nebraska Plant
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: